Vestibo, pills 16mg 30pcs

Composition

1 tablet contains:

Active ingredient:

betahistine dihydrochloride 16 mg;

Auxiliary substances:

povidone K90;

MCC;

lactose monohydrate;

colloidal silicon dioxide;

crospovidone;

stearic acid;

purified water (not contained in the finished product).

Pharmacological action

Vestibo-histamine-like, vasodilating.

Pharmacodynamics

It is a weak agonist_{of H1}-receptors and a fairly powerful antagonist_{of H3}-receptors. It affects the cochlear blood flow and the central vestibular apparatus.

The action of betahistine includes: vasodilation in the inner ear (mediated_{by H3-and H1}-receptors), an inhibitory effect on the vestibular nuclei (via_H3-receptors) and the pulse activity of ampullary receptors.

By direct agonistic action on the_H1-receptors of the inner ear vessels and precapillary sphincters of the microcirculatory bed located in the vascular strip (stria vascularis), as well as indirectly through the_H3-receptors, it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea, increases blood flow in the basilar artery.

It has a pronounced central effect, being an antagonist_{of H3}-receptors of the vestibular nerve nuclei, normalizes neuronal transmission in polysynaptic neurons of the vestibular nuclei at the level of the brain stem. Indirectly acting on_H3-receptors, it increases the content of serotonin in the brain stem, which reduces the activity of the vestibular nuclei. Helps to eliminate disorders of both the vestibular and cochlear apparatus: reduces the frequency and intensity of dizziness, reduces tinnitus, improves hearing in cases of its decline. It stimulates_H1-receptors, so it does not have a sedative effect and does not cause drowsiness.

Pharmacokinetics

Absorbed quickly, binding to plasma proteins is low. _Cmax — 3 h. It is almost completely excreted by the kidneys as a metabolite (2-pyridylacetic acid) within 24 h. T_1/2 — 3-4 h.

Indications

• dropsy of the inner ear labyrinth;
• vestibular and labyrinth disorders: dizziness, noise and pain in the ears, headache, nausea, vomiting, hearing loss; vestibular neuritis, labyrinthitis, benign positional vertigo (including after neurosurgical operations), Meniere’s disease.
• As part of complex therapy:
• vertebrobasilar insufficiency;
• post-traumatic encephalopathy;
• cerebral vascular atherosclerosis.

Contraindications

• hypersensitivity;
• pheochromocytoma;
• bronchial asthma;
• gastric ulcer and

Side effects

Dyspepsia (nausea, vomiting), skin rash, angioedema.

How to take, course of use and dosage

Inside, while eating, without chewing, with a small amount of liquid.

8-16 mg 2-4 times a day.

Long-term treatment.

Overdose

Symptoms:  headache, hyperemia of the facial skin, dizziness, tachycardia, decreased blood pressure Blood pressure, bronchospasm.

Special instructions

The therapeutic effect in some cases appears only a few months after the start of treatment.

Form of production

Tablets

Storage conditions

Store the drug in a dry place protected from light at a temperature not exceeding 22°C.

Shelf life

2 years

Active ingredient

Betahistine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as prescribed by a doctor, For adults

Indications

Cerebrovascular accident, Meniere ‘s Disease